GGrantIndex
Sort

48,018 grants matching immunotherapy

Tumor selective inhibition of the WNT pathway

$568,218
Lukas Edward Dow · Weill Medical Coll Of Cornell Univ · R01 · FY2023 · CA

Adoptive immunotherapy after umbilical cord blood transplant

$568,179
Laurence J.n. Cooper · University Of Tx Md Anderson Can Ctr · R01 · FY2009 · CA

Finding the optimal balance of immunotherapy efficacy and toxicity.

$568,167
David Eric Gerber · Ut Southwestern Medical Center · U01 · FY2023 · AI

Testing the role of BATF as a pioneer transcription factor in effector T cells

$568,163
William Nicholas Haining · Dana-Farber Cancer Inst · R01 · FY2015 · AI

Metabolic control of human endothelial development via the COUP-TF/1-deoxysphingosine axis

$568,115
Natalia B Ivanova · University Of Georgia · R01 · FY2025 · HL

Specific Adoptive Immunotherapy of Leukemia

$568,090
Philip D Greenberg · Fred Hutchinson Cancer Research Center · P01 · FY2010 · CA

Credentialing Models of Invasive Lobular Breast Cancer for Translational Research

$568,084
Steffi Oesterreich · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA

Coordinating Center for Canine Immunotherapy Trials and Correlative Studies

$567,985
Nicola J Mason · University Of Pennsylvania · U24 · FY2021 · CA

METASTATIC COLORECTAL CANCER IMMUNOTHERAPY WITH GUCY2C-EXPRESSING LISTERIA MONOCYTOGENES

$567,969
Thomas Jefferson University · · FY2017 · Department of the Army

Tissue-Targeted Enzyme for Localized Tryptophan Catabolism to Direct Subcutaneous and Oral Mucosal Inflammatory Responses

$567,817
Benjamin George Keselowsky · University Of Florida · R01 · FY2017 · DE

Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy

$567,816
Wen Jiang · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA

Development of new passive immunization strategies for anthrax

$567,768
Arturo Casadevall · Columbia University Health Sciences · U54 · FY2011 · AI

Image-guided TRAIL-enhanced CAR T-cell immunotherapy

$567,760
Vladimir Ponomarev · Sloan-Kettering Inst Can Research · R01 · FY2020 · CA

Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia

$567,734
Brian T Campfield · University Of Pittsburgh At Pittsburgh · R01 · FY2024 · HL

Development of selective HDAC6 inhibitors to improve cancer immunotherapy

$567,683
Alejandro V Villagra · Georgetown University · R01 · FY2024 · CA

Engineered extracellular vesicles derived from mesenchymal stem cells for the treatment of type 1 diabetes

$567,641
Ryang Hwa Lee · Texas A&M University Health Science Ctr · R01 · FY2024 · DK

VIRAL IMMUNOTHERAPY TO ERADICATE SUBCLINICAL BRAIN METASTASES

$567,503
University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2011 · Department of Defense

Cytek Aurora CS

$567,400
Eric P Skaar · Vanderbilt University Medical Center · S10 · FY2023 · OD

Career Development in Pediatric and Medical Oncology

$567,345
Soheil Meshinchi · Fred Hutchinson Cancer Center · K12 · FY2023 · CA

Coordinating Center for Canine Immunotherapy Trials and Correlative Studies

$567,292
Nicola J Mason · University Of Pennsylvania · U24 · FY2020 · CA

Targeting KRAS and adenosine mediated immunosuppression in pancreatic cancer

$567,204
Caius Gabriel Radu · University Of California Los Angeles · R01 · FY2024 · CA

MECHANISMS OF MURINE TUMOR ERADICATION BY IMMUNOTHERAPY

$567,199
Philip D Greenberg · University Of Washington · R37 · FY2006 · CA

Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors

$567,157
Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2021 · CA

Dendritic Cell mediated induction of Anti-HCV immunity

$567,063
Nina Bhardwaj · New York University School Of Medicine · R01 · FY2007 · AI

Project 3: Combinatorial and gene-editing approaches to enhance the efficacy of CAR T cell therapy of multiple myeloma.

$567,040
Edward A Stadtmauer · University Of Pennsylvania · P01 · FY2021 · CA